BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-222@pharmaconomics
DTSTAMP:20260707T005012Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:ROIV PDUFA — brepocitinib (estimated date)
DESCRIPTION:The FDA's approval decision on brepocitinib for dermatomyositis is due ~ Sep 30\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1635088/000114036126007447/ef20066998_8k.htm\n\nTrack it: https://www.pharmaconomics.com/e/222
URL:https://www.pharmaconomics.com/e/222
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ROIV catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR